FDA Panel Meets to Review Pfizer's COVID-19 Vaccine for Kids 5-11

A panel of U.S. health advisers Tuesday begins discussions on whether or not the FDA should grant emergency authorization to Pfizer’s COVID-19 vaccine for children ages 5 to 11. Thom Jensen reports.